Escitalopram: A review of its use in the management of major depressive disorder

Drugs

Volumn 65, Issue 16, 2005, Pages 2379-2404

  Murdoch, David ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

depression; Escitalopram; major depressive disorder; pharmacodynamics; pharmacoeconomics; pharmacokinetics; therapeutic efficacy; tolerability

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; ESCITALOPRAM; PLACEBO; VENLAFAXINE;

AREA UNDER THE CURVE; COMORBIDITY; COMPARATIVE STUDY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG COST; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EJACULATION DISORDER; HAMILTON SCALE; HEALTH CARE COST; HUMAN; HYPERHIDROSIS; INSOMNIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; NAUSEA; QUALITY OF LIFE; RATING SCALE; RELAPSE; REVIEW; SCORING SYSTEM; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOMNOLENCE; STEADY STATE; SUICIDE; SUSTAINED DRUG RELEASE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; SEROTONIN ANTAGONISTS;

EID: 27644432393     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565160-00013     Document Type: Review

References (94)

1. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17 (5): 343-62
2. Croom K, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003; 21 (16): 1185-209
3. Eccles M, Freemantle N, Mason J. North of England evidenced-based guide development project: summary version of guidelines for the choice of antidepressants for depression in primary care. The North of England Anti-depressant Guideline Development Group. Fam Pract 1999; 16 (2): 103-11
4. Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatment (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001; 46 Suppl. 1: 1S-92S
5. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999; 60 Suppl. 17: 41-5
6. Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol 1999; 14 Suppl. 1: S27-31
7. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18 (13): 911-32
8. Fernandez JL, Montgomery S, François C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23 (2): 155-67
9. Institute for Clinical Systems Improvement. Health care guideline: major depression in adults in primary care [online]. Available from URL: http://www.isci.org [Accessed 2005 Jul 17]
10. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical guideline 23. London: National Institute for Clinical Excellence, 2004 Dec
11. Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004; 18 (8): 505-20
12. Śanchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003 Jun; 167 (4): 353-62
13. Forest Laboratories Inc. Lexapro. (escitalopram oxalate) US prescribing information [online]. Available from URL: http:// www.fda.gov [Accessed 2005 Jul 17]
14. H. Lundbeck AS. Cipralex: European summary of product characteristics [online]. Available from URL: http:// www.cipralex.com/images/Cipralex/smpc.pdf [Accessed 2005 Jul 17]
15. Lundbeck Canada Inc. Annotated prescribing information: escitalopram. Canada: Lundbeck Canada Inc., 2005
16. Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J Clin Psychopharmacol 2004 Apr; 24 (2): 209-13
17. Owens MJ, Knight DL, Nemeroff CB. Second-generation SS-RIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-50
18. Chen F, Larsen MB, Sánchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005 Mar; 15 (2): 193-8
19. Mørk A, Kreilgaard M, Śanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003 Aug; 45 (2): 167-73
20. Storustovu S, Sánchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004 May; 142 (1): 172-80
21. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004 Feb; 77 (2): 391-8
22. Mitchell PJ, Hogg S. Behavioral effects of escitalopram predict potent antidepressant activity [abstract no. 401]. Biol Psychiatry 2001; 49 Suppl.: 115S
23. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004 Sep; 29 (9): 1699-703
24. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005 Apr; 66 (4): 436-43
25. Sánchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004 Jul; 174 (2): 163-76
26. Chen F, Larsen MB, Neubauer HA, et al. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005 Jan; 92 (1): 21-8
27. Sánchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003 Sep; 14 (5-6): 465-70
28. El Mansari M, Sánchez C, Chouvet G, et al. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005; 30: 1269-77
29. 1A receptors. Br J Pharmacol 2004 Jun; 142 (3): 469-78
30. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. In Press
31. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 Aug; 29 (8): 1102-9
32. Areberg J, Christophersen JS, Poulsen MN, et al. Pharmacokinetics of escitalopram in subjects with hepatic impairment [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28-Jul 3; Vienna
33. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 2005; 60 (3): 287-90
34. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003 Apr; 25 (4): 1200-10
35. Preskorn SH, Klick-Davis A, Coyner L, et al. The effect of escitalopram versus sertraline versus duloxetine on CYP 2D6 function [abstract no. NR877 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21-26; Atlanta (GA), 326
36. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20 (3): 131-7
37. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 Jul; 18: 211-7
38. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well-tolerated in the treatment of severe depression [abstract no. NR 486 plus poster]. New Research Abstracts: American Psychiatric Association 2003 Annual Meeting; 2003 May 17-22; San Francisco (CA), 182
39. Forest Laboratories Inc. SCT-MD-26 [online]. Available from URL: http://forestclinicaltrials.com [Accessed 2005 Sep 6]
40. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr; 63 (4): 331-6
41. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 May; 17 (3): 95-102
42. Colonna L, Andersen HF, Reines EH. A randomized, doubleblind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Res Med Opin 2005; 21 (10): 1659-68
43. Vaya L, Appaya PM, Hegde RP, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Ind J Psychiatry 2004; 46: 333-41
44. Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder [abstract no. 54]. Neuropsychopharmacology 2004; 29 Suppl. 1: 87.
45. Plus poster presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12-16; San Juan, Puerto Rico
46. Baldwin D, Hindmarch I, Huusom AKT. Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD) [abstract no. P01.135]. Int J Neuropsychopharmacol 2004 Jun 22; 7 Suppl. 1: S168
47. Plus poster presented at the 24th Congress of the Collegium Internationale Neuropsychopharmacologicum; 2004 Jun 20-24; Paris
48. Alexopoulos GS, Privitera W, Ventura D, et al. Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50-200 mg/day) in a randomised, double-blind comparison in depressed patients [abstract no. 6257]. World J Biol Psychiatry 2004; 5 Suppl. 1: 97
49. Plus poster presented at the International Congress of Biological Psychiatry; 2004 Feb 9-13; Sydney
50. Forest Laboratories Inc. SCT-MD-27 [online]. Available from URL: http://forestclinicaltrials.com [Accessed 2005 Sep 12]
51. Clayton A, Wightman D, Modell JG, et al. Effects in MDD on sexual functioning of bupropion XL, escitalopram, and placebo in depressed patients [abstract no. NR-818 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21-26; Atlanta (GA), 303
52. Wightman D, Horrigan JP, Modell JG, et al. The tolerability and safety of bupropion XL versus escitalopram in the treatment of major depressive disorder [poster]. 13th Congress of the Association of European Psychiatrists (AEP); 2005 Apr 2-6; Munich
53. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65 (9): 1190-6
54. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50 (1): 57-64
55. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21 (1): 26-32
56. Möller HJ, Lotze K, Langer S. postmarketing surveillance of escitalopram in depressed outpatients [abstract no. PO-021.10]. World J Biol Psychiatry 2005; 6 Suppl. 1: 282-283.
57. Plus poster presented at the 8th World Congress of Biological Psychiatry; 2005 Jun 28-Jul 3; Vienna
58. Zimbroff DL, Bose A, Li D. Escitalopram treatment of SSRI nonresponders can lead to remission in patients who fail initial SSRI therapy [abstract no. NR758 plus poster]. 157th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2004 May 1-6; New York
59. Wade A, Despiegel N, Reines EH. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. In Press
60. Kornstein SG, Bose A, Li D. Maintenance treatment with escitalopram prevents recurrence of depressive episodes [abstract no. NR744 plus poster]. 157th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2004 May 1-6; New York, 279-80
61. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004 Jan; 65 (1): 44-9
62. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005 Mar; 59 (3): 268-75
63. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004 May; 19 (3): 149-55
64. Auquier P, Robitail S, Llorca PM, et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003; 7 (4): 259-68
65. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002 Apr; 7 (4 Suppl. 1): 40-4
66. Wade A, Andersen HF. Onset of effect of escitalopram; a pooled analysis [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28-Jul 3; Vienna
67. Bandelow B, Anderson HF. Escitalopram in the treatment of anxiety associated with depression [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28-Jul 3; Vienna
68. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004 Sep; 19 (5): 305-10
69. Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients. Hum Psychopharmacol 2005; 20: 349-54
70. Kennedy SH, Anderson EA. Short-term efficacy of escitalopram treatment of MDD: a pooled analysis versus SSRIs and venlafaxine [abstract no. NR873 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21-26; Atlanta (GA), 325
71. Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004 Sep; 7 (3): 283-90
72. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005 Apr; 21 (4): 631-41
73. Hemels MEH, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004 Jun; 38 (6): 954-60
74. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005 Apr; 27 (4): 486-96
75. François C, Toumi M, Aakhus AM, et al. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4 (1): 12-9
76. Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005 Jan; 27 (1): 111-24
77. Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004 Jun; 20 (6): 869-78
78. Löthgren M, Hemels M, François C, et al. A cost-effectiveness analysis of escitalopram as first-line treatment of depression in Sweden. Prim Care Psych 2004; 9 (4): 153-61
79. Hemels M. Probabilistic cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in the Netherlands. 5th World Congress of the International Health Economics Association; 2005 Jul 10-13; Barcelona, 140-1
80. Armstrong EP, Skrepnek GH, Malone DC, et al. A cost-effectiveness analysis of escitalopram and sertraline in the treatment of major depressive disorder [abstract no. PMH28]. Value Health 2005; 8 (3): 393
81. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91-107
82. Kulp W, Greiner W, Schulenburg JM. Cost-effectiveness of escitalopram vs. venlafaxine XR in the treatment of major depressive disorder in Germany [abstract no. PMH27]. Value Health 2005; 8 (3): 392-3.
83. Plus poster presented at ISPOR 10th Annual Meeting; 2005 May 15-18; Washington, DC
84. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87
85. Baldwin DA, Montgomery SA, Nil R, et al. Discontinuation symptoms in affective disorders [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28-Jul 3; Vienna
86. Kasper S, de Swart H, Anderson HF, et al. Escitalopram in the treatment of depressed elderly patients. Am J Ger Psychiatr. In Press
87. Gersing K, Taylor L, Mereadith C. Outcomes and adverse events for escitalopram and sertraline in a real-world setting [abstract no. NR815 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21-26; Atlanta (GA)
88. Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/ SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31: 257-62
89. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385-8
90. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 2005 May; 20 (3): 139-43
91. Magnuson TM, Burke WJ. Clinical experience with escitalopram, a stereoisomer antidepressant. Todays Ther Trends 2003; 21 (2): 117-26
92. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004 Jun; 38 (6): 389-407
93. Ashton AK. Reversal of fluoxetine-induced sexual dysfunction by switching to escitalopram [letter]. J Sex Marital Ther 2004; 30: 1-2
94. US Food and Drug Administration. FDA talk paper: FDA reviews data for antidepressant use in adults [online]. Available from URL: http://www.fda.gov/ bbs/topics/ANSWERS/2005/ANS01362.html [Accessed 2005 Sep 9]